How much support do you need
Although a prior cohort study did not show a statistically significant reduction in major cardiovascular events among patients with no previous history of cardiovascular disease [148], a meta-analysis of eight clinical trials evaluating the effect of GLP-1R agonists on cardiovascular outcomes reported a 14% reduction in major adverse cardiovascular events, with no significant heterogeneity across GLP-1R agonists or subgroups, including patients with or without previous cardiovascular disease [149]
You can edit or delete your press release Glucagon-like Peptide 1 (GLP-1) Analogues Market Growth, Trends, and Key Players 2025- Eli Lilly and Company, Novo Nordisk A/S., Sanofi
(You can now subscribe to our Economic Times WhatsApp channel) (Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates.
We are still learning the best approach, but for now, its best to plan for long-term use